Shanghai-based antibody drug conjugate (ADC) specialist Phrontline Biopharma has reportedly secured over RMB 100 million (USD 13.8 million) in a pre-Series A financing round, with funds exclusively provided by Decheng Capital. The capital raised will be directed towards bolstering research and development efforts, pre-clinical development, and the enhancement of its proprietary technology platforms.
Established in 2022, Phrontline Bio has developed an in-house technology platform that encompasses four key technologies essential for ADC drugs: toxins, linkers, coupling methods, and antibodies. The company also possesses platforms for antibody discovery, bispecific antibody preparation, Linker Payload design and synthesis, and fixed-point quantitative coupling technology.- Flcube.com
